Twist Bioscience (NASDAQ:TWST) Reaches New 12-Month High – What’s Next?

Twist Bioscience Corporation (NASDAQ:TWST) shares hit a new 52-week high during trading on Monday . The company traded as high as $80.79 and last traded at $78.9580, with a volume of 233794 shares traded. The stock had previously closed at $76.17.

Wall Street Analyst Weigh In

A number of brokerages have commented on TWST. Piper Sandler began coverage on Twist Bioscience in a research report on Thursday. They issued an “overweight” rating and a $85.00 price target for the company. UBS Group set a $89.00 target price on Twist Bioscience in a research report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Friday, March 27th. Leerink Partners set a $80.00 target price on Twist Bioscience in a research report on Friday, May 22nd. Finally, TD Cowen set a $89.00 target price on Twist Bioscience in a research report on Monday. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Twist Bioscience presently has a consensus rating of “Moderate Buy” and a consensus price target of $71.60.

Twist Bioscience Price Performance

The company has a current ratio of 2.70, a quick ratio of 2.42 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $5.10 billion, a P/E ratio of -61.57 and a beta of 2.23. The stock has a 50 day moving average of $59.67 and a 200-day moving average of $47.58.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, May 4th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.22). The firm had revenue of $110.72 million for the quarter, compared to the consensus estimate of $107.64 million. Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The company’s revenue for the quarter was up 19.3% on a year-over-year basis. During the same period last year, the firm earned ($0.66) earnings per share. On average, equities research analysts anticipate that Twist Bioscience Corporation will post -2.02 earnings per share for the current fiscal year.

Insider Transactions at Twist Bioscience

In related news, Director Robert Chess sold 10,000 shares of the business’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $47.00, for a total transaction of $470,000.00. Following the transaction, the director directly owned 21,084 shares in the company, valued at $990,948. The trade was a 32.17% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jan Johannessen sold 12,000 shares of the business’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $56.12, for a total value of $673,440.00. Following the transaction, the director owned 17,754 shares in the company, valued at approximately $996,354.48. This trade represents a 40.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 43,170 shares of company stock worth $2,418,964. Company insiders own 3.08% of the company’s stock.

Institutional Trading of Twist Bioscience

Hedge funds have recently modified their holdings of the stock. Quarry LP purchased a new stake in shares of Twist Bioscience in the third quarter worth about $28,000. Smartleaf Asset Management LLC increased its holdings in shares of Twist Bioscience by 70.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock valued at $29,000 after purchasing an additional 442 shares during the last quarter. Western Wealth Management LLC acquired a new stake in shares of Twist Bioscience in the first quarter valued at approximately $31,000. Strs Ohio acquired a new stake in shares of Twist Bioscience in the first quarter valued at approximately $33,000. Finally, Strategic Advocates LLC increased its holdings in shares of Twist Bioscience by 562.7% in the fourth quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock valued at $34,000 after purchasing an additional 906 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.